Seroprevalence of chikungunya virus infection among HIV-infected adults in French Caribbean Islands of Martinique and Guadeloupe in 2015: A cross-sectional study

Elodie Curlier, Laurence Fagour, Cécile Herrmann-Storck, Adrien Staelen, Ingrid Vingadassalom, Sébastien Breurec, Sylvie Abel, Sandrine Pierre-François, Janick Jean-Marie, Cédric Laouénan, Raymond Césaire, Bruno Hoen, André Cabié, Elodie Curlier, Laurence Fagour, Cécile Herrmann-Storck, Adrien Staelen, Ingrid Vingadassalom, Sébastien Breurec, Sylvie Abel, Sandrine Pierre-François, Janick Jean-Marie, Cédric Laouénan, Raymond Césaire, Bruno Hoen, André Cabié

Abstract

Background: In 2014, a first outbreak of chikungunya hit the Caribbean area where chikungunya virus (CHIKV) had never circulated before.

Methodology/principal findings: We conducted a cross-sectional study to measure the seroprevalence of CHIKV immediately after the end of the 2014 outbreak in HIV-infected people followed up in two clinical cohorts at the University hospitals of Guadeloupe and Martinique. Study patients were identified during the first months of 2015 and randomly selected to match the age and sex distribution of the general population in the two islands. They were invited to complete a survey that explored the symptoms consistent with chikungunya they could have developed during 2014 and to have a blood sample drawn for CHIKV serology. The study population consisted of 377 patients (198 in Martinique and 179 in Guadeloupe, 178 men and 199 women), 182 of whom reported they had developed symptoms consistent with chikungunya. CHIKV serology was positive in 230 patients, which accounted for an overall seroprevalence rate of 61% [95%CI 56-66], with only 153 patients who reported symptoms consistent with chikungunya. Most frequent symptoms included arthralgia (94.1%), fever (73.2%), myalgia (53.6%), headache (45.8%), and skin rash (26.1%).

Conclusions/significance: This study showed that the seroprevalence of CHIKV infection was 61% after the 2014 outbreak, with one third of asymptomatic infections.

Trial registration: ClinicalTrials.gov NCT02553369.

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Dorléans F, Hoen B, Najioullah F, Herrmann-Storck C, Schepers KM, Abel S, et al.. Outbreak of Chikungunya in the French Caribbean Islands of Martinique and Guadeloupe: Findings from a Hospital-Based Surveillance System (2013–2015). Am J Trop Med Hyg. 2018;98(6):1819–25. 10.4269/ajtmh.16-0719
    1. Halstead SB. Reappearance of Chikungunya, Formerly Called Dengue, in the Americas. Emerg Infect Dis. 2015;21(4). 10.3201/eid2104.141723
    1. Pugliese P, Cuzin L, Cabié A, Poizot-Martin I, Allavena C, Duvivier C, et al.. A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med. 2009;10(8):504–11. 10.1111/j.1468-1293.2009.00719.x
    1. Gallian P, Leparc-Goffart I, Richard P, Maire F, Flusin O, Djoudi R, et al.. Epidemiology of Chikungunya Virus Outbreaks in Guadeloupe and Martinique, 2014: An Observational Study in Volunteer Blood Donors. PLOS Negl Trop Dis. 2017;11(1):e0005254. 10.1371/journal.pntd.0005254
    1. Renault P, Solet JL, Sissoko D, Balleydier E, Larrieu S, Filleul L, et al.. A Major Epidemic of Chikungunya Virus Infection on Reunion Island, France, 2005 2006. Am J Trop Med Hyg. 2007;77(4):727–31.
    1. Gérardin P, Guernier V, Perrau J, Fianu A, Le Roux K, Grivard P, et al.. Estimating Chikungunya prevalence in La Réunion Island outbreak by serosurveys: two methods for two critical times of the epidemic. BMC Infect Dis. 2008;8:99. 10.1186/1471-2334-8-99
    1. Sissoko D, Moendandze A, Malvy D, Giry C, Ezzedine K, Solet JL, et al.. Seroprevalence and Risk Factors of Chikungunya Virus Infection in Mayotte, Indian Ocean, 2005–2006: A Population-Based Survey. PLOS ONE. 2008;3(8):e3066. 10.1371/journal.pone.0003066
    1. Rogier EW, Moss DM, Mace KE, Chang M, Jean SE, Bullard SM, et al.. Use of Bead-Based Serologic Assay to Evaluate Chikungunya Virus Epidemic, Haiti. Emerg Infect Dis. 2018;24(6):995–1001. 10.3201/eid2406.171447
    1. Prat CM, Flusin O, Panella A, Tenebray B, Lanciotti R, Leparc-Goffart I. Evaluation of commercially available serologic diagnostic tests for chikungunya virus. Emerg Infect Dis. 2014;20(12):2129–32. 10.3201/eid2012.141269
    1. Kositpantawong N, Charoenmak B, Siripaitoon P, Silpapojakul K. Clinical Presentations and Interactions of the Chikungunya Viral Infection in HIV Patients During the Chikungunya Epidemic in Southern Thailand. Open Forum Infect Dis. 2014;1(suppl_1):S462–3.
    1. Institut national de la statistique et des études économiques. Statistiques et études. Available from .
    1. Milligan GN, Schnierle BS, McAuley AJ, Beasley DWC. Defining a correlate of protection for chikungunya virus vaccines. Vaccine. 2018;in press. 10.1016/j.vaccine.2018.10.033
    1. Silva JVJ, Ludwig-Begall LF, Oliveira-Filho EF de, Oliveira RAS, Durães-Carvalho R, Lopes TRR, et al.. A scoping review of Chikungunya virus infection: epidemiology, clinical characteristics, viral co-circulation complications, and control. Acta Trop. 2018;188:213–24. 10.1016/j.actatropica.2018.09.003

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner